Although the role of RIG‐I as a prognostic marker varies across cancer types, its activation consistently induces apoptotic tumour cell death and impacts immune response by increasing infiltration of immune cells into the tumour, enhancing their anti‐cancer effects and reducing immunosuppressive activities (Besch et al., 2009; Bourquin et al., 2020; Das et al., 2019; Duewell et al., 2014; Ellemeier et al., 2013; D. Peng et al., 2020). Here, RIGI is linked to cancer.